Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Molina Healthcare (MOH), Erasca (ERAS) and Pharvaris (PHVS)

Tipranks - Tipranks - Tue Feb 10, 8:02AM CST

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Molina Healthcare (MOH – Research Report), Erasca (ERAS – Research Report) and Pharvaris (PHVS – Research Report).

Valentine's Day Sale - 70% Off

Molina Healthcare (MOH)

Cantor Fitzgerald analyst Sarah James maintained a Hold rating on Molina Healthcare yesterday and set a price target of $144.00. The company’s shares closed last Friday at $131.72.

According to TipRanks.com, James is a 4-star analyst with an average return of 4.1% and a 53.5% success rate. James covers the Healthcare sector, focusing on stocks such as Acadia Healthcare, HCA Healthcare, and UnitedHealth. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Molina Healthcare with a $181.70 average price target, which is a 44.2% upside from current levels. In a report issued on February 7, TipRanks – OpenAI also downgraded the stock to Hold with a $130.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Erasca (ERAS)

In a report released today, Laura Prendergast from Stifel Nicolaus maintained a Buy rating on Erasca, with a price target of $10.00. The company’s shares closed last Friday at $12.29.

According to TipRanks.com, Prendergast is a 4-star analyst with an average return of 32.7% and a 59.3% success rate. Prendergast covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Foghorn Therapeutics, and Revolution Medicines. ;'>

Erasca has an analyst consensus of Moderate Buy, with a price target consensus of $10.88, representing a -8.9% downside. In a report issued on January 26, Mizuho Securities also initiated coverage with a Buy rating on the stock with a $16.00 price target.

Pharvaris (PHVS)

In a report released today, Maxwell Skor from Morgan Stanley maintained a Buy rating on Pharvaris, with a price target of $41.00. The company’s shares closed last Friday at $26.42.

According to TipRanks.com, Skor is a 5-star analyst with an average return of 20.8% and a 66.3% success rate. Skor covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Crinetics Pharmaceuticals, and Monopar Therapeutics Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Pharvaris with a $41.00 average price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).